Met-Rx
American brand of nutritional supplements
MET-Rx is an American brand of nutritional supplements originally produced by Met-Rx, Inc., a California company started by Scott Connelly and sold several times since. The brand created a category of bodybuilding supplements called meal replacement powders or MRPs. It was also involved in the androstenedione controversy in the late 1990s.
Company
Created by Scott Connelly, an anesthesiologist, the original MET-Rx product was intended to help prevent critically ill patients from losing muscle mass. Connelly's product was marketed in cooperation with Bill Phillips, and the two began marketing to the bodybuilding and athletic communities, launching sales from the low hundreds of thousands to over $100 million annually. Connelly sold all interest in the company to Rexall Sundown for $108 million in 2000. MET-Rx is owned by NBTY.
Products
Original MET-Rx MRP
The original MET-Rx meal replacement product came in two canisters—one labeled MET-Rx "base" and the other MET-Rx "plus". The instructions were to take two scoops of the plus and one scoop of the base and mix them in milk or water. MET-Rx's meal replacements and protein powders contain a proprietary blend (known as "Metamyosyn") which consists of ingredients such as whey protein, calcium caseinate, egg albumen and milk protein isolate, combined with maltodextrin, vitamins, minerals and added amino acids. As the product grew more popular, it was released as one formula combining the "base" and "plus" while removing the micellar casein component.
“Met-Rx” enters the record as american brand of nutritional supplements. Crown Archives preserves that source wording while asking what Met-Rx, American and brand can confirm, complicate or overturn.
Why this record matters
“Met-Rx” is worth following because a concise public description often conceals a longer documentary argument. Here, Met-Rx, American and brand provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 6, 2026. The linked authority identifier is Q6822223. 1 of 1 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 2000.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Met-Rx”, its source revision and the description used here.
- Expand the search: follow Met-Rx primary sources, Met-Rx archive and Met-Rx research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Met-Rx”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Met-Rx” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.